Showing posts with label Rheumatoid Arthritis. Show all posts
Showing posts with label Rheumatoid Arthritis. Show all posts

Monday, 6 May 2019

Rheumatoid Arthritis: Global Drug Forecast and Market Analysis to 2027

Researchmoz added Most up-to-date research on "Rheumatoid Arthritis: Global Drug Forecast and Market Analysis to 2027" to its huge collection of research reports. An insight on the important factors and trends influencing the market.
Rheumatoid arthritis (RA) is an autoimmune disease that, due to a complex interplay of environmental, immunological, and genetic factors, causes chronic inflammation and progressive deformity of the joints over time.
In 2017, the diagnosed prevalence of RA in the 8MM averaged 0.66% in adults 18 years of age and older and 2.7% in adults aged 60 and older. Early RA typically presents as a bilateral inflammatory joint condition, usually beginning in the smaller joints such as the fingers and toes and eventually progressing to the larger joints. Patients can experience flare-ups early in the disease onset, which are typically worse in the morning. Over time, pain and swelling may become constant, ultimately leading to deformity.
Request Free Sample Pages Of This Premium Research Report: https://www.researchmoz.us/enquiry.php?type=S&repid=2303798
Key Question Answered
With the increased entry of biosimilars into the RA marketplace, sales growth has begun to slacken and will likely continue to slow over the next 10 years.
- How will biosimilar uptake differ cross the 8MM ?
- What companies and drugs will be most affected by sales erosion from biosimilars?
Key Opinion Leaders (KOLs) interviewed by GlobalData have indicated that there are still many remaining unmet needs within the RA indication.
- What are the main unmet needs in the RA market?
- How can the pharmaceutical industry address these needs?
- To what degree will the therapies under development fulfill these unmet needs?
Although biosimilars may slow the growth of the RA market, GlobalData expects that pipeline development of agents in the JAK inhibitor class as well as other novel oral agents , will powerfully shape the RA market going forward.
- What are the main R&D trends in the RA market and which companies are leading the way?
- Are there major differences in the mechanisms of action used by therapies in late-stage versus early stage clinical development?
Scope
- Overview of RA including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Topline RA therapeutics market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
- Key topics covered current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting RA therapeutics sales in the 8MM.
- Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global RA therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Contact For Discount or to Get Customized Report: https://www.researchmoz.us/enquiry.php?type=E&repid=2303798
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global RA therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RA market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global RA therapeutics market from 2017-2027.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfil all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organisations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us

For More Reports Visit @ http://marketresearchlatestreports.blogspot.com/

Thursday, 22 February 2018

Rheumatoid Arthritis Global Market Research Report: 2016 Edition | AbbVie, JNJ, Amgen Inc., Pfizer Inc.

Researchmoz added Most up-to-date research on "Global Rheumatoid Arthritis Market Report: 2016 Edition" to its huge collection of research reports.

Arthritis means inflammation in a joint. Inflammation is a normal immune response in a body. It happens when the body, no longer has the ability to turn off the inflammatory response and thereby start damaging the healthy tissues of the body. This inflammation causes redness, warmth, swelling, and pain within the joint. There are more than 100 different types of arthritis, with different causes and treatment methods. Major classification of arthritis includes degenerative arthritis, inflammation arthritis, infectious and metabolic arthritis.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=746067

Rheumatoid arthritis or RA is classified under inflammatory arthritis. It is a chronic autoimmune disease. About 1 out of every 5 people who suffer from rheumatoid arthritis get lumps on their skin called rheumatoid nodules. This disease occurs in 4 main stages and can be diagnosed with certain blood tests, medical history, and imaging tests. There is no cure for rheumatoid arthritis, but there are various treatments available that reduce the pain like drugs, physical exercise or surgery.

The rheumatoid arthritis market is expected to grow in the coming years with growing demand for better medical facilities and more effective drugs. The US rheumatoid arthritis market dominates the global market with larger number of rheumatoid arthritis patients. The key trends of the market include increasing competition from anti-IL6 drugs, rising FDA approvals to RA drugs, use of complementary and alternative medicines, and increasing share of biosimilars.

The key factors driving the growth of the RA market includes increasing women population, escalating global ageing population, rising health care expenditure, rising cigarette consumption, and increasing obese population. However, there are certain factors which hinder the growth of the rheumatoid arthritis market like high cost of treatment and high research and development cost.

The report offers an in-depth analysis of the “Global Rheumatoid Arthritis Market” segmented into global and regional market. Competition is concentrated in the hands of few major pharmaceutical companies. Major RA companies that have been covered in the report include AbbVie, JNJ, Amgen Inc. and Pfizer Inc.

Table of Content

1. Market Overview
1.1 Arthritis
1.2 Types of Arthritis
1.2 Rheumatoid Arthritis
1.3 Causes
1.4 Stage
1.5 Diagnosis
1.6 Treatment Options

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/global-rheumatoid-arthritis-market-report-2016-edition-report.html/toc

2 Global Market
2.1 Global Rheumatoid Arthritis Market by Value
2.2 Global Rheumatoid Arthritis Market by Drug Class
2.3 Global Rheumatoid Market Share by Drug
2.4 Global Rheumatoid Arthritis Market Share by Biologics

3. The U.S. Market
3.1 The US Rheumatoid Arthritis Market by Value
3.2 The US Rheumatoid Arthritis Patient Prevalence
3.3 The US Rheumatoid Arthritis Patient Penetration
3.4 The US Rheumatoid Arthritis Anti TNF Population
3.5 The US Rheumatoid Arthritis Biologics Population

4. Market Dynamics
4.1 Key Trends
4.1.1 Increasing Competition from Anti IL 6 Drugs
4.1.2 Rising FDA Approvals to Rheumatoid Arthritis Drugs
4.1.3 Auto Injectors for Rheumatoid Arthritis
4.1.4 Use of Complementary and Alternative Medicines (CAMs)
4.1.5 Increasing Biosimilars for Rheumatoid Arthritis
4.2 Growth Drivers
4.2.1 Increasing Female Population Worldwide
4.2.2 Escalating Global Ageing Population
4.2.3 Rising Global Health Care Expenditure
4.2.4 Rising Cigarette Consumption
4.2.5 Increasing Obese Population
4.3 Challenges
4.3.1 High Cost of Treatment
4.3.3 High R&D Cost

5. Competitive Landscape
5.1 Global Market
5.1.1 Rheumatoid Arthritis Market Share by Company
5.1.2 Rheumatoid Arthritis Market Competition by Anti TNF
5.1.3 Rheumatoid Arthritis Competition by Biologics
5.2 The US Market
5.2.1 Rheumatoid Arthritis Brand (Company) Share

Continue...

Friday, 19 May 2017

Global Drug Forecast and Market Analysis on PharmaPoint: Rheumatoid Arthritis to 2025

Researchmoz added Most up-to-date research on "PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025" to its huge collection of research reports.

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over six million individuals in the 8MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, and Australia) and this prevalence is expected to grow to just shy of 7 million individuals by 2025. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2015 and 2025. With the anti-TNFs as extremely effective for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars launch across the 8MM and begin to gain traction in these markets.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1070540

Scope

- Overview of rheumatoid arthritis (RA), including etiology, pathophysiology, and country-specific diagnosis and treatment recommendations.
- Annualized RA market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the RA biologics and biosimilars markets.
- Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically JAK inhibitors (such as Eli Lilly/Incytes Olumiant (baricitinib), novel biologics (such as AstraZeneca-MedImmunes mavrilimumab), and biosimilars (such as Celltrion/Hospira/Pfizers Inflectra/Remsima, Samsung Bioepis/Biogen/Mercks Flixabi and Benepali, Sandozs Erelzi, and Amgens Amjevita).
- Analysis of the current and future market competition in the global RA market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the RA market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RA market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the eight major RA markets from 2015-2025.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1070540

Friday, 5 May 2017

Global Rheumatoid Arthritis Market Key Trends, Size, Growth, Shares And Forecast Research Report 2016

Researchmoz added Most up-to-date research on "Global Rheumatoid Arthritis Market Report: 2016 Edition" to its huge collection of research reports.

Arthritis means inflammation in a joint. Inflammation is a normal immune response in a body. It happens when the body, no longer has the ability to turn off the inflammatory response and thereby start damaging the healthy tissues of the body. This inflammation causes redness, warmth, swelling, and pain within the joint. There are more than 100 different types of arthritis, with different causes and treatment methods. Major classification of arthritis includes degenerative arthritis, inflammation arthritis, infectious and metabolic arthritis.

Rheumatoid arthritis or RA is classified under inflammatory arthritis. It is a chronic autoimmune disease. About 1 out of every 5 people who suffer from rheumatoid arthritis get lumps on their skin called rheumatoid nodules. This disease occurs in 4 main stages and can be diagnosed with certain blood tests, medical history, and imaging tests. There is no cure for rheumatoid arthritis, but there are various treatments available that reduce the pain like drugs, physical exercise or surgery.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=746067

The rheumatoid arthritis market is expected to grow in the coming years with growing demand for better medical facilities and more effective drugs. The US rheumatoid arthritis market dominates the global market with larger number of rheumatoid arthritis patients. The key trends of the market include increasing competition from anti-IL6 drugs, rising FDA approvals to RA drugs, use of complementary and alternative medicines, and increasing share of biosimilars.

The key factors driving the growth of the RA market includes increasing women population, escalating global ageing population, rising health care expenditure, rising cigarette consumption, and increasing obese population. However, there are certain factors which hinder the growth of the rheumatoid arthritis market like high cost of treatment and high research and development cost.

The report offers an in-depth analysis of the “Global Rheumatoid Arthritis Market” segmented into global and regional market. Competition is concentrated in the hands of few major pharmaceutical companies. Major RA companies that have been covered in the report include AbbVie, JNJ, Amgen Inc. and Pfizer Inc.

Table of Content

1. Market Overview
1.1 Arthritis
1.2 Types of Arthritis
1.2 Rheumatoid Arthritis
1.3 Causes
1.4 Stage
1.5 Diagnosis
1.6 Treatment Options

2 Global Market
2.1 Global Rheumatoid Arthritis Market by Value
2.2 Global Rheumatoid Arthritis Market by Drug Class
2.3 Global Rheumatoid Market Share by Drug
2.4 Global Rheumatoid Arthritis Market Share by Biologics

3. The U.S. Market
3.1 The US Rheumatoid Arthritis Market by Value
3.2 The US Rheumatoid Arthritis Patient Prevalence
3.3 The US Rheumatoid Arthritis Patient Penetration
3.4 The US Rheumatoid Arthritis Anti TNF Population
3.5 The US Rheumatoid Arthritis Biologics Population

4. Market Dynamics
4.1 Key Trends
4.1.1 Increasing Competition from Anti IL 6 Drugs
4.1.2 Rising FDA Approvals to Rheumatoid Arthritis Drugs
4.1.3 Auto Injectors for Rheumatoid Arthritis
4.1.4 Use of Complementary and Alternative Medicines (CAMs)
4.1.5 Increasing Biosimilars for Rheumatoid Arthritis
4.2 Growth Drivers
4.2.1 Increasing Female Population Worldwide
4.2.2 Escalating Global Ageing Population
4.2.3 Rising Global Health Care Expenditure
4.2.4 Rising Cigarette Consumption
4.2.5 Increasing Obese Population
4.3 Challenges
4.3.1 High Cost of Treatment
4.3.3 High R&D Cost

5. Competitive Landscape
5.1 Global Market
5.1.1 Rheumatoid Arthritis Market Share by Company
5.1.2 Rheumatoid Arthritis Market Competition by Anti TNF
5.1.3 Rheumatoid Arthritis Competition by Biologics
5.2 The US Market
5.2.1 Rheumatoid Arthritis Brand (Company) Share

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=746067

Thursday, 4 May 2017

Recent Study on Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation

Researchmoz added Most up-to-date research on "Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation" to its huge collection of research reports.
Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable auto-immune disease that affects the joints, and is characterized by synovial inflammation and hyperplasia. It occurs when a number of aberrant cell signaling events trigger chronic inflammation of the synovium – the soft tissue of the joint – leading to pain, joint stiffness, and eventually deformity and disability.

With the disease affecting 0.3–1.0% of the global population, the societal and economic costs of RA are substantial. The large target patient population and the relatively high annual cost of therapy have resulted in a crowded, highly lucrative market.

Treatment options have improved and diversified substantially over the past two decades, largely owing to the advent of biologics. Despite this, considerable unmet needs remain within RA. Consequently, opportunities for future drug developments remain significant, particularly for first-in-class innovation, which is the area most likely to produce substantial clinical advances.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=799450

Scope

- Treatment options for RA have advanced over the past two decades, resulting in a crowded, competitive market landscape.
- What is the pathophysiology of RA?
- Which products and therapeutic strategies dominate the clinical and commercial landscapes?
- What are the most significant unmet needs within the RA market?
- Considerable diversification from current market trends is evident within the RA pipeline.
- Which molecular targets are most prominent within the pipeline?
- What proportion of pipeline products are first in class?
- Which first-in-class targets are most promising?
- Deal values for licensing and co-development deals vary considerably.
- How many strategic consolidations have been completed in the past decade?
- Which types of assets attract the largest deal values?
- Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Reasons To Buy

This report will allow you to:

- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, diagnosis, and treatment options.
- Visualize the composition of the RA landscape, including key unmet needs, in order to gain a competitive understanding of gaps in the current market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, all first-in-class targets in the RA pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
- Identify first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=799450

Monday, 10 April 2017

Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation | Now Available at Researchmoz.us

Researchmoz added Most up-to-date research on "Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation" to its huge collection of research reports.

Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable auto-immune disease that affects the joints, and is characterized by synovial inflammation and hyperplasia. It occurs when a number of aberrant cell signaling events trigger chronic inflammation of the synovium – the soft tissue of the joint – leading to pain, joint stiffness, and eventually deformity and disability.

With the disease affecting 0.3–1.0% of the global population, the societal and economic costs of RA are substantial. The large target patient population and the relatively high annual cost of therapy have resulted in a crowded, highly lucrative market.

Treatment options have improved and diversified substantially over the past two decades, largely owing to the advent of biologics. Despite this, considerable unmet needs remain within RA. Consequently, opportunities for future drug developments remain significant, particularly for first-in-class innovation, which is the area most likely to produce substantial clinical advances.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=799450

Scope

- Treatment options for RA have advanced over the past two decades, resulting in a crowded, competitive market landscape.
- What is the pathophysiology of RA?
- Which products and therapeutic strategies dominate the clinical and commercial landscapes?
- What are the most significant unmet needs within the RA market?
- Considerable diversification from current market trends is evident within the RA pipeline.
- Which molecular targets are most prominent within the pipeline?
- What proportion of pipeline products are first in class?
- Which first-in-class targets are most promising?
- Deal values for licensing and co-development deals vary considerably.
- How many strategic consolidations have been completed in the past decade?
- Which types of assets attract the largest deal values?
- Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Reasons To Buy

This report will allow you to:

- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, diagnosis, and treatment options.
- Visualize the composition of the RA landscape, including key unmet needs, in order to gain a competitive understanding of gaps in the current market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, all first-in-class targets in the RA pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
- Identify first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=799450

Blood Thawing System Market Insights Shared in Detailed Report

Blood Thawing System Market: Introduction According to the report, the global  blood thawing system market  was valued at ~US$ 174 Mn in 2...